Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.14, $0.03 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $14.4 million versus the consensus estimate of $18.2 million.

For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.

Earnings